Author at Microdose

Madison Roberts

Madison Roberts is a nomadic journalist exploring the intersections of cutting-edge science, tech and human well-being. She immerses in diverse cultures, uncovering compelling stories in biotech, neuropsychiatry, neuroscience, mental health, psychedelics and longevity research. Her writing blends scientific rigor with human narratives, resonating across readers. Passionate about the brain's intricacies and psychedelics' healing potential, she's a thought-provoking, empathetic storyteller. Between interviews and breakthroughs, Madison cherishes tranquil moments exploring new landscapes.

Finance

8 May 2024

A Pioneering Push in Cancer Treatment: Enveric Biosciences Advances with Cannabinoid Therapies

Enveric Biosciences, a notable player in biotechnological innovations, has recently announced a significant licensing agreement that might change the landscape of cancer treatment....

By Madison Roberts

Press Releases

8 May 2024

Enveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids

Enveric Biosciences announced that it has signed a non-binding term sheet with an undisclosed biotechnology development and commercialization company to exclusively out-license two patent families of Methods for Treating Breast...

By Madison Roberts

Press Releases

7 May 2024

Numinus Wellness Focused on Boosting Profitability and Expanding Community Support

As part of the strategic plan, Numinus has entered into an agreement with the Canadian Centre for Psychedelic Healing ("Field Trip Health"), which provides psychedelic-assisted therapy in five Canadian clinics...

By Madison Roberts

Science

6 May 2024

Innovating CNS Disorder Treatment: EQUULUS and the Revolutionary Approach with Analog Ibogaine

Navigating the complex landscape of pharmaceutical development for central nervous system (CNS) disorders is no small feat. Current treatments vary widely, from antipsychotics to antidepressants and mood stabilizers. However, for...

By Madison Roberts

Join Our Newsletter for Exclusive Updates, Stories, and More

Science

3 May 2024

Ketamine-Assisted Psychotherapy for Chronic Pain and Depression

Chronic pain and depression are major health crises in the United States, significantly affecting the quality of life for millions. Traditional treatments often fall short in providing relief, leading to...

By Madison Roberts

Press Releases

2 May 2024

Reunion Neuroscience Inc. Announces $103 Million Series A Financing Co-Led by MPM BioImpact and Novo Holdings

Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to pushing the boundaries of neuroscience, today announced the close of a $103 million Series A financing co-led by MPM BioImpact and...

By Madison Roberts

Science

1 May 2024

Harnessing Ketamine for Complex Psychiatric Cases: A Dual Diagnosis Approach

In the rapidly evolving landscape of psychiatric care, innovative treatments like ketamine assisted psychotherapy (KAP) hold promise for addressing complex, comorbid conditions that traditional therapies often struggle to manage....

By Madison Roberts

Breaking News

30 Apr 2024

MindBio Therapeutics Announces Landmark Women’s Health CNS Drug Trials

MindBio Therapeutics Corp, a clinical stage biopharma company developing innovative psychiatric treatments using microdoses of psychedelic medicines to revolutionize mental health treatments, is delighted to announce the regulatory approval of...

By Madison Roberts

Finance

29 Apr 2024

Unlocking New Horizons: Enveric Biosciences’ Strategic Moves in Biotechnology

Enveric Biosciences has signed two non-binding term sheets to out-license novel cannabinoid-COX-2 conjugate compounds for joint disease treatment, with potential financial gains from milestone payments and royalties totaling up to...

By Madison Roberts

Follow us on social

Latest News

You Might Also Like

9 Feb 2026

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

For much of the last decade, psychedelic medicine has been driven by clinical outcomes first and mechanistic explanations second. Promising results in depression, anxiety, and trauma propelled compounds like psilocybin...

By Madison Roberts

19 Jan 2026

Starting 2026: Why Neuroplastogens Are Quietly Redefining the Psychedelic Medicine Narrative

An industry wide look at how neuroplastogens are reshaping psychedelic medicine in 2026, with insights on Delix, AbbVie’s Gilgamesh acquisition, Enveric, and the shift toward nonhallucinogenic brain therapeutics....

By Madison Roberts

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

WordPress Ads